Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: Implications for conversion to lamotrigine monotherapy

Epilepsy Research

Volumn 57, Issue 2-3, 2003, Pages 85-93

  Gidal, Barry E ^a   Sheth, Raj ^a   Parnell, Jennifer ^b   Maloney, Kathy ^c   Sale, Mark ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Lamotrigine (LTG); Lennox Gastaut syndrome; VPA dose

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0842330657     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2003.09.008     Document Type: Article

References (21)

1. Anderson G.D., Yau M.K., Gidal B.E.et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin. Pharmacol. Ther. 60:1996;145-156.
2. Armijo J.A., Bravo J., Cuadrado A., Herranz J.L. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther. Drug Monit. 21(2):1999;182-190.
3. Battino D., Estienne M., Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin. Pharmacokinet. 29(4):1995;257-286.
4. Battino D., Croci D., Granata T., Estienne M., Pisani F., Avanzini G. Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther. Drug Monit. 19(6):1997;620-627.
5. Battino D., Croci D., Granata T., Mamoli D., Messina S., Perucca E. Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. Ther. Drug Monitor. 23(3):2001;217-222.
6. Biton V., Natarajan S., Ramsay R.E.et al. Dosing algorithm for conversion from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. Neurology. 60:2003;A476. (Abstract).
7. Brodie M.J., Yuen A.W.C.et al. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res. 26:1997;423-432.
8. Dulac O., Kaminska A. Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J. Child Neurol. 12(Suppl. 1):1997;S23-S28.
9. Faught E., Morris G., Jacobson M., French J., Harden C., Montouris G., Rosenfeld W. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia. 40(8):1999;1135-1140.
10. Garnett W.R. Lamotrigine: pharmacokinetics. J. Child Neurol. 12(Suppl. 1):1997;S10-S15.
11. Gidal B.E., Anderson G.D., Lanning A., Shaw R., Rutecki P. Lack of effect of VPA concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res. 42:2000;23-31.
12. Green M.D., Bishop W.P., Tephley T.R. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab. Dispos. 23:1995;299-302.
13. Hawes E.M. N-Glucuronidation a common pathway in human drug metabolism of drugs with a tertiary amine group. Drug Metab. Dispos. 26:1998;830-837.
14. Kanner A.M., Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology. 55:2000;588-591.
15. Magdalou J., Heber R., Biaault R.et al. In-vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine by human liver microsomes. J. Pharmacol. Exp. Ther. 260:1992;1166-1173.
16. Motte J., Trevathan E., Arvidsson J.F., Barrera M.N., Mullens E.L., Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N. Engl. J. Med. 7337(25):1999;1807-1812.
17. Peck A.W. Clinical pharmacology of lamotrigine. Epilepsia. 32(Suppl. 2):1991;S9-S12.
18. Pisani F., Oteri G.et al. The efficacy of valproate-lamotrigine comedication in refractory complex-partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 40:1999;1141-1146.
19. Rambeck B., Wolf P. Lamotrigine clinical pharmocokinetics. Clin. Pharmacokinet. 25:1993;433-443.
20. Wong I.C., Mawer G.E., Sander J.W. Factors influencing the incidence of lamotrigine-related skin rash. Ann. Pharmacother. 33(10):1999;1037-1042.
21. Yuen A.W., Land G., Weatherley B.C., Peck A.W. Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Clin. Pharmacol. 33(5):1992;511.